A risk stratification tool has been developed that enables the prediction of the 10-year risk of patients with obesity developing type 2 diabetes. Dr W Timothy Garvey (University of Alabama at Birmingham, Birmingham, AL, USA) discusses the tool, named Cardiometabolic Disease Scoring, the impact of semaglutide on the risk of developing type 2 diabetes and the implications for prevention.
The abstract entitled ‘Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- How did you assess the 10-year risk of type 2 diabetes using data from the STEP program? (0:26)
- What impact did semaglutide have on the 10-year risk of developing diabetes, including the effect of baseline glycaemic status on results? (2:31)
- In your opinion, what are the implications of this study’s results for preventing type 2 diabetes in overweight and obese people? (4:00)
Disclosures: W Timothy Garvey is on the advisory board for Alnam, Boehringer-Ingelheim, Eli Lilly, Fractyl, JAZZ Pharmaceuticals, Novo Nordisk and Pfizer. W Timothy Garvey has received grant/research support from Eli Lilly, Epitomee, Novo Nordisk and Pfizer. All clinical trials were sponsored by the University of Alabama at Birmingham.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Obesity
Domenica Rubino, EASD 2022: The Role of Semaglutide in the Treatment Paradigm for Prediabetes
Semaglutide has clinically beneficial effects on glucose metabolism and glycaemic status in patients with obesity and prediabetes. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses her thoughts on the role of semaglutide in the treatment paradigm for prediabetes. The abstract entitled: ‘Semaglutide 2.4 mg […]
Domenica Rubino, EASD 2022: Semaglutide 2.4 mg vs Liraglutide 3.0 mg on Glucose Metabolism – STEP 8 Post-hoc analysis
The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the […]
Uberto Pagotto, ESPE 2022: GLP-1 Agonists and Other Emerging Treatments of Obesity
Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity. In this touchENDOCRINOLOGY interview, Prof. Uberto Pagotto (University of Bologna, Bologna, Italy) discusses the impact of glucagon-like peptide 1 agonists on obesity, what other emerging treatments in obesity appear promising. The future direction in obesity research is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!